Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single stranded RNA virus, and is responsible for the pandemic outbreak called COVID-19. The pandemic, still ongoing, had presented unprecedented challenges in terms of finding appropriate pharmacological treatments. Methods Starting from the recent literature that demonstrates how ALKBH5 inhibitors could be used as a new strategy to reduce SARS-CoV-2 replication, we decided to repurpose our newly discovered ALKBH5 inhibitor MV1035, previously tested and proved effective against glioblastoma, for its putative antiviral activity against SARS-CoV-2. We demonstrated a reduction in SARS-CoV-2-induced CPE after 72 h incubation using MV1035 (50 µM), for SARS-CoV-2 wild type (Wuhan strain) and South African variant. Results and conclusion The results show how MV1035 seems to be able to reduce SARS-CoV-2 replication through an indirect mechanism of action, which might involve an interaction with the host cell rather than with a virus protein.

Potential in-vitro antiviral activity of MV1035 on SARS-CoV-2 wild type viruses / Benincasa, Linda; Molesti, Eleonora; Manenti, Alessandro; Montomoli, Emanuele; Malacrida, Alessio; Zuliani, Valentina; Rivara, Mirko; Nicolini, Gabriella; Di Domizio, Alessandro. - In: LETTERS IN DRUG DESIGN & DISCOVERY. - ISSN 1875-628X. - 20:10(2023), pp. 1656-1663. [10.2174/1570180819666220701105250]

Potential in-vitro antiviral activity of MV1035 on SARS-CoV-2 wild type viruses

Valentina Zuliani;Mirko Rivara
;
2023-01-01

Abstract

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single stranded RNA virus, and is responsible for the pandemic outbreak called COVID-19. The pandemic, still ongoing, had presented unprecedented challenges in terms of finding appropriate pharmacological treatments. Methods Starting from the recent literature that demonstrates how ALKBH5 inhibitors could be used as a new strategy to reduce SARS-CoV-2 replication, we decided to repurpose our newly discovered ALKBH5 inhibitor MV1035, previously tested and proved effective against glioblastoma, for its putative antiviral activity against SARS-CoV-2. We demonstrated a reduction in SARS-CoV-2-induced CPE after 72 h incubation using MV1035 (50 µM), for SARS-CoV-2 wild type (Wuhan strain) and South African variant. Results and conclusion The results show how MV1035 seems to be able to reduce SARS-CoV-2 replication through an indirect mechanism of action, which might involve an interaction with the host cell rather than with a virus protein.
2023
Potential in-vitro antiviral activity of MV1035 on SARS-CoV-2 wild type viruses / Benincasa, Linda; Molesti, Eleonora; Manenti, Alessandro; Montomoli, Emanuele; Malacrida, Alessio; Zuliani, Valentina; Rivara, Mirko; Nicolini, Gabriella; Di Domizio, Alessandro. - In: LETTERS IN DRUG DESIGN & DISCOVERY. - ISSN 1875-628X. - 20:10(2023), pp. 1656-1663. [10.2174/1570180819666220701105250]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2944631
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact